Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The St. Louis Post-Dispatch reports that the Missouri Department of Health and Senior Services awarded a no-bid contract to the Missouri Primary Care Association. The agreement will pay the organization $125,000 a year to focus on getting more adolescents to receive at least five vaccines, including influenza, hepatitis A and HPV. Contract talks began before health officials warned last week that a hepatitis A outbreak in the state could grow worse if it spreads to urban areas. Health officials say the state has recorded 414 cases of the virus since September 2017. In previous years, only about 10 cases were reported annually.
[A]: State awards contract to boost hepatitis A vaccination rate.


[Q]: Major U.S. indexes fell about 2 percent and the Dow Jones Industrial Average dropped as much as 563 points. On the benchmark S&P 500 index, health care and technology companies absorbed the worst losses. Johnson & Johnson plunged by the most in 16 years after Reuters reported that the company has known since the 1970s that its talc Baby Powder sometimes contained carcinogenic asbestos. The company denied the report. China said industrial output and retail sales both slowed in November. That could be another sign that China’s trade dispute with the U.S. and tighter lending conditions are chilling its economy, which is the second-largest in the world. Meanwhile, purchasing managers in Europe signaled that economic growth was slipping. Sameer Samana, senior global market strategist for Wells Fargo Investment Institute, said investors are concerned that weakness will make it way to the U.S. They’re wondering if the U.S. economy is likely to run out of steam sooner than they had thought. “Market consensus has been that the next recession is probably in 2020 or beyond,” he said. Now, he said, the market is “really testing that assumption and trying to figure out whether it’s sooner.” Rising interest rates and tighter credit conditions are adding to investors’ nervousness because they both tend to slow down economic growth. This week the European Central Bank said it is ending a bond-buying program that has pumped trillions into Europe’s economy. The Federal Reserve is expected to increase U.S. rates again on Wednesday, as it’s been doing for the last three years. It may also shed light on whether it plans to raise rates further in 2019. For more than 20 years, China has been one of the biggest contributors to growth in the global economy, and when investors see signs the Chinese economy is weakening, they expect it will affect other countries like the U.S. that sell things to China. In Europe, the index of purchase managers fell in France, which is racked by protests, to a level that points toward economic contraction. Germany’s reading still pointed to growth, but it fell to its lowest level in four years. Those reports canceled out some potential good news on trade: the Chinese government announced a 90-day suspension of tariff increases on U.S. cars, trucks and auto imports. It’s part of a cease-fire that China and the U.S. announced earlier this month to give them time to work on other issues. December is typically the best month of the year for stocks as a “Santa Claus rally” often adds to the year’s gains. With 10 trading days left this month, however, the S&P 500 is down 5.8 percent. That followed a small gain in November and a steep 6.9 percent drop in October. The S&P 500 index lost 50.59 points, or 1.9 percent, to 2,599.95, its lowest close since April 2. The Dow retreated 496.87 points, or 2 percent, to 24,100.51. The Dow has fallen 10 percent from its record high in early October, reaching a mark known on Wall Street as a “correction.” The other major U.S. indexes were already in “corrections.” The Nasdaq composite slid 159.67 points, or 2.3 percent, to 6,910.66. The Russell 2000 index of smaller-company stocks fell 21.89 points, or 1.5 percent, to 1,410.81. Johnson & Johnson dropped 10 percent to $133 in very heavy trading. Its market value fell by $40 billion. Reuters reported that court documents and test results show Johnson & Johnson has known for decades that its raw talc and finished Baby Powder sometimes contained asbestos, but that the company didn’t inform regulators or the public. The company called the story “false and inflammatory.” In July the company lost a lawsuit from plaintiffs who argued that its products were linked to cases of ovarian cancer and mesothelioma. A St. Louis jury awarded plaintiffs $4.7 billion. Johnson & Johnson faces thousands of other lawsuits. Among technology companies, Apple dipped 3.2 percent to $165.48. Adobe skidded 7.3 percent to $230 after its fourth-quarter profit disappointed investors and it also forecast lower-than-expected earnings in the current fiscal year. Industrial companies sank as well. Boeing lost 2.1 percent to $318.75. Oil prices again turned lower, as a slower global economy would weaken demand for oil and other fuels. Benchmark U.S. crude fell 2.6 percent to $51.20 a barrel in New York. Brent crude, used to price international oils, dropped 1.9 percent to settle at $60.28 a barrel in London. European Union leaders rejected British Prime Minister Theresa May’s request to make changes to their deal covering Britain’s departure from the EU on March 29. British legislators aren’t satisfied with the terms May negotiated, and she canceled a scheduled vote earlier this week because it was clear Parliament wouldn’t approve it. Britain’s economy and financial markets across Europe face severe disruption without an agreement. In other trading: —European bond prices rose and yields fell. Both the British pound and the euro weakened. The pound slipped to $1.2579 from $1.2660 and the euro fell to $1.1303 from $1.1367. —Germany’s DAX declined 0.5 percent and the CAC 40 in France declined 0.8 percent. Britain’s FTSE 100 fell 0.5 percent. —Japan’s Nikkei 225 index slid 2 percent and the Kospi in South Korea lost 1.3 percent. Hong Kong’s Hang Seng was down 1.6 percent. —Bond prices edged higher. The yield on the 10-year Treasury note fell to 2.89 percent 2.90 percent. —In other commodities trading, wholesale gasoline lost 3 percent to $1.43 a gallon. Heating oil fell 1.7 percent to $1.85 a gallon and natural gas dropped 7.2 percent to $3.83 per 1,000 cubic feet. —Gold fell 0.5 percent to $1,241.40 an ounce. Silver dipped 1.5 percent to $14.64 an ounce. Copper was little changed at $2.77 a pound. —The dollar fell to 113.29 yen from 113.60 yen. ____ Associated Press Writer Josh Boak contributed to this report from Washington. ___ AP Markets Writer Marley Jay can be reached at http://twitter.com/MarleyJayAP
[A]: Stocks plunge to 8-month lows on growth fears; J&J nosedives.


[Q]: Data from the 236-patient trial, which lasted 13 weeks and  compared the effectiveness of Cymbalta with placebos, were  presented at the annual congress of the European Federation of  Neurological Societies in Madrid. Lilly said 31 percent of patients taking Cymbalta  experienced a 50 percent reduction in pain, as measured by a  standard pain scale, compared with 19 percent of  placebo-treated patients. But significantly more patients taking Cymbalta dropped out  of the trial because of side effects, which included nausea,  dry mouth, fatigue, diarrhea, excessive sweating, dizziness and  constipation. Lilly said side effects were similar to those seen in  previous trials of Cymbalta for other conditions. Global second-quarter sales of Cymbalta, one of Lilly’s  biggest products, jumped 26 percent to $654 million, helped by  its other approved uses to treat fibromyalgia and generalized  anxiety disorder. The drug works by maximizing the presence of two messenger  chemicals in the brain, serotonin and norepinephrine.
[A]:
Lilly depression drug eases back pain in study.